A
VERA icon

Abingworth’s Vera Therapeutics VERA Stock Holding History

Abingworth’s Portfolio VERA Stock Details VERA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		$57.3M Hold
2,960,231
– – 18.66% 3
2022
Q3 		$63.1M Hold
2,960,231
– – 21.57% 2
2022
Q2 		$40.3M Hold
2,960,231
– – 12.9% 3
2022
Q1 		$69.3M Hold
2,960,231
– – 19.66% 2
2021
Q4 		$78.5M Hold
2,960,231
– – 19.03% 2
2021
Q3 		$51.4M Hold
2,960,231
– – 11.66% 4
2021
Q2 		$38.5M Buy
+2,960,231
New +$46M 11.91% 3

Other funds holding VERA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Abingworth's VERA Position: Q4 2022 in Review

Abingworth held its Vera Therapeutics (VERA) position steady in Q4 2022 at 2,960,231 shares worth $57.3M. The position accounts for 18.66% of the portfolio, ranked #3.

Abingworth first reported a position in VERA in Q2 2021 and has held it in 7 quarters since. The position peaked at $78.5M in Q4 2021. 59 funds tracked by Wall St. Rank hold VERA as of Q4 2022.

  • Abingworth held 2,960,231 shares of Vera Therapeutics worth $57.3M as of Q4 2022.
  • Abingworth left its Vera Therapeutics share count unchanged in Q4 2022.
  • Vera Therapeutics made up 18.66% of Abingworth's portfolio in Q4 2022, its #3 holding.
  • Abingworth first reported a position in Vera Therapeutics in Q2 2021 and has held it in 7 quarters since.
  • Abingworth's Vera Therapeutics position peaked at $78.5M in Q4 2021.
  • 59 funds tracked by Wall St. Rank held Vera Therapeutics as of Q4 2022.

Based on Abingworth's 13F filing for Q4 2022, filed 10 Feb 2023.